Last reviewed · How we verify
Plenaxis
At a glance
| Generic name | Plenaxis |
|---|---|
| Sponsor | PRAECIS Pharmaceuticals Inc. |
| Target | Gonadotropin-releasing hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Ischemic priapism
Common side effects
Key clinical trials
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Diagnosis of Pelvic Endometriosis in MRI (NA)
- Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer (PHASE3)
- The Plenaxis® Experience Study (PHASE4)
- Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plenaxis CI brief — competitive landscape report
- Plenaxis updates RSS · CI watch RSS
- PRAECIS Pharmaceuticals Inc. portfolio CI